Gaitril is developed by State University of New York - Upstate Medical University.

What development phase is Gaitril in?

Gaitril is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Gaitril

State University of New York - Upstate Medical University · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Gaitril
Sponsor	State University of New York - Upstate Medical University
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Switching From an SSRI to Tiagabine(GABITRIL) in Order to Alleviate SSRI Induced Sexual Dysfunction (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Gaitril CI brief — competitive landscape report
Gaitril updates RSS · CI watch RSS
State University of New York - Upstate Medical University portfolio CI